Sirtris Pharmaceutical, which develops drugs to treat aging-related diseases, announced the terms of its IPO Wednesday. The company plans to offer 5 million shares at a price range of $9.00 to $11.00 per share. JPMorgan and CIBC are bookrunning the deal.
